| A20 | Combination therapy with the broadly neutralizing antibody VRC07'523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+ T cell infection or reduce low-level viremia | Oral abstract session with live Q&A | Eliminating and silencing latency |
| A18 | The passenger hypothesis: HIV exploits CD4 T cell homeostasis to promote long-term persistence of its reservoirs | Oral abstract session with live Q&A | Cellular and tissue reservoirs of HIV/SIV |
| A17 | Identifying host genetic determinants of HIV-1 reservoir markers reveals PTDSS2 and IRF7 as potential modifying factors in HIV-1 patients | Oral abstract session with live Q&A | Host cellular factors and latency |
| A18 | Naïve CD4+ T cells form the bulk of the translation competent HIV-1 reservoir in vertically infected children and adolescents | Oral abstract session with live Q&A | Cellular and tissue reservoirs of HIV/SIV |
| B11 | Early termination of randomisation into TB-PRACTECAL, a novel six months all-oral regimen Drug Resistant TB study | Oral abstract session with live Q&A | Tuberculosis and other mycobacteria |
| B11 | High rate of successful outcomes treating highly resistant TB in the ZeNix study of pretomanid, bedaquiline and alternative doses and durations of linezolid | Oral abstract session with live Q&A | Tuberculosis and other mycobacteria |
| B10 | Single high-dose liposomal amphotericin based regimen for treatment of HIV-associated Cryptococcal Meningitis: results of the phase-3 Ambition-cm Randomised Trial | Oral abstract session with live Q&A | Opportunistic infections (excluding tuberculosis) |
| B78 | Unsuppressed plasma HIV-RNA viral load is associated with worse COVID-19 outcomes among people living with HIV | Oral abstract session with live Q&A | COVID-19 morbidity and mortality in PLWH |
| B39 | Long-acting subcutaneous lenacapavir dosed every 6 months as part of a combination regimen in treatment-naïve people with HIV: interim 16-week results of a randomized, open-label, phase 2 induction-maintenance study (CALIBRATE) | Oral abstract session with live Q&A | Long-acting agents and other drug delivery systems |
| B35 | Switching to the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a 3-drug regimen through 24 weeks in a randomized clinical trial (SALSA) | Oral abstract session with live Q&A | Regimen simplification and switch studies |